Skip to main content
Clinical Trials/NL-OMON54913
NL-OMON54913
Completed
Phase 4

A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers. - Deep phenotyping of vulvar (pre)malignant disease.

Centre for Human Drug Research0 sites40 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Centre for Human Drug Research
Enrollment
40
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Non\-pregnant female subjects, 25\-95 years of age (inclusive); in general,
  • stable good health as per judgment of the investigator based upon the results
  • of a medical history, physical examination (BMI \* 30\) and vital signs.
  • 2\. BMI of \* 30
  • 3\. If female of childbearing potential, have a negative urine pregnancy test at
  • 4\. Willing to give written informed consent and willing and able to comply with
  • the study protocol.
  • 5\. Ability to communicate well with the investigator in the Dutch or English
  • 6\. Subject is willing to undergo vulvar biopsies.
  • 7\. Subject is willing to refrain from washing (including bathing, swimming,

Exclusion Criteria

  • 1\. Significant, uncontrolled or unstable disease in any organ system as per
  • judgment of the investigator (regardless of association with the
  • immunosuppressing disorder/therapy), including but not limited to: psychiatric,
  • neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal,
  • endocrine, hematologic or respiratory disease.
  • 2\. History of immunological abnormality (e.g., immune suppression) that may
  • interfere with study objectives, in the opinion of the investigator.
  • 3\. Known infection requiring (topical or oral) antibiotic therapy within 28
  • days prior to Day 0;
  • 4\. The use of any oral/systemic medication (e.g. immunomodulatory,

Outcomes

Primary Outcomes

Not specified

Similar Trials